Tagged with Novartis,

Healthcare PharmaBoardroom has spoken to a wide variety of actors at the cutting edge of healthcare digitalization over the past 12 months. Hot topics have included the healthcare industry’s slow reaction to digital trends, new modes of hospital care, homecare, and digitalization’s potential to expand access in remote and underdeveloped areas.…

Singapore Christopher Snook discusses his dual role as Head of Group Country Management as well as Country President for Singapore, highlighting the importance of adhering to in-house as well as country-specific regulatory frameworks and the continued importance of Singapore to the global group.   We will continue to see Singapore in…

Switzerland Frederic Bengold, MD of Servier Switzerland, on the affiliate’s main growth drivers, an exciting collaboration with Novartis on heart failure medication, and the intricacies of market access in Switzerland. Could you please start by introducing Servier’s Swiss affiliate? We enjoy a longstanding presence and reputation in Switzerland. The local affiliate…

Philippines Cheryl Maley, General Manager of Novartis Philippines, discusses the company’s operations in the country, their growing portfolio of products as well as their impressive focus on research and development in the Philippines. She also discusses some of her key objectives and goals for her first country leadership role. As an…

Philippines Bakhuti Shengelia, Director Healthcare Systems of Novartis International AG, expands on Novartis’ initiatives to increase access to healthcare in emerging markets as well as the importance of transitioning towards value-based healthcare systems to improve healthcare outcomes. He also discusses how emerging markets are able leverage the fact they have more…

Luxembourg Novartis’ newest Head for the Grand-Duchy of Luxembourg provides a fascinating insight into the Luxembourg market and reveals how this small nation has found itself in pole position for future pharmaceutical innovation. After over a decade with GSK, you joined Novartis one and half years ago. What made you join…

Switzerland It is tempting to characterize Switzerland’s global pharma and life science hotspots as beginning and ending with Basel – home of industry giants Roche and Novartis. However, Zurich, Geneva, and even tiny Zug are all now staking serious claims for global recognition in this area. “Zurich is the world’s smallest…

Slovakia Novartis Slovakia’s Marianthi Psaha discusses the upcoming shift in Slovakia’s healthcare landscape, the importance of a healthy dialogue between the public and private sectors, and the responsibility of the pharma industry to continuously strive for the highest standards of compliance, integrity and performance. You have been Country President for Slovakia…

Mexico Alexis Serlin, country president of Novartis Mexico and president of CANIFARMA, the industry chamber that brings together multinational and local drug manufacturers, explains how the pharmaceutical industry in Mexico aims to be recognized as a strategic sector by both the Ministries of Health and Economy. He highlights Novartis Mexico’s leadership in…

Novartis Dr Ann Aerts, head of the Novartis Foundation, discusses the role the Novartis Foundation plays within low and middle- income countries across the world and how integrating digital health solutions can strengthen health systems and contribute to global health.   We at the Novartis Foundation can leverage the expertise of…

Pharma Daniel Breitenstein, VP and GM of GSK Switzerland, discusses the benefits of GSK’s three-part transaction with Novartis; the importance of respiratory diseases and vaccines for future success; and how the company has changed its business model by no longer paying for physicians to speak on their behalf, setting in process…

Novartis Novartis Czech Republic’s Heidrun Irschik explains the potentially game-changing ramifications of Big Data on the Czech pharmaceutical and healthcare industries.   The opportunities offered by big data are present and we need to tap into this immense potential Heidrun Irschik, Novartis Big data: a technological phenomenon with potential commensurate to…